Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial
Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl TWP, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Hoffmann O, Muller L, Wimberger P, Ruckhaeberle E, Blohmer J, Janni W (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: AMER ASSOC CANCER RESEARCH
City/Town: PHILADELPHIA
Conference Proceedings Title: CANCER RESEARCH
DOI: 10.1158/1538-7445.sabcs20-pd3-12
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Technische Universität Dresden
Germany (DE)
Heinrich-Heine-Universität Düsseldorf
Germany (DE)
Asklepios Kliniken
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Technische Universität Dresden
Germany (DE)
Heinrich-Heine-Universität Düsseldorf
Germany (DE)
Asklepios Kliniken
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
How to cite
APA:
Fehm, T., Mueller, V., Banys-Paluchowski, M., Fasching, P., Friedl, T.W.P., Hartkopf, A.,... Janni, W. (2021). Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MLA:
Fehm, Tanja, et al. "Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.
BibTeX: Download